- Apr2020 interview with Dr. Rob Sambursky, CEO of Lumos Diagnostics; he is the lead developer of the FebriDx test method.
(25:22 length); if people prefer verbal explanations, he runs through what his test is about and its market potential
- FebriDx RDT approved for sale in AU, EU region + Canada, Pakistan, Singapore currently.
- US clinical trials seem to be underway for US FDA approval.
- In above April interview, Dr Sambursky mentions Covid19 infection fears slowed down the takeup of US volunteers for the trial, as less people were visiting clinics for diagnosis + safety of trial technicians caused extreme caution. This situation might have changed since then....can't find more info yet on status.
I missed connecting some dots correctly earlier:
- AT1 announced OEM supply to RPS Diagnostics on 20 Feb 2018 for FebriDx tests (Dr Sambursky was the company MD and developed FebriDx test);
https://atomodiagnostics.com/joint-press-announcement-rps-diagnostics-and-atomo-diagnostics/- as mentioned in earlier post, RPS Diagnostics then merged with Lumos Diagnostics and the AT1 hookup has continued on. Dr Sambursky moved over as Lumos Diagnostics CEO.
Anyway, the point of all this, is the long term potential of FebriDx as a major global disrupter for screening viral vs bacterial infection, at initial diagnosis stage, by any and every doctor or hospital. The more this test need is understood, verified and adopted as a 'typical must-do test', the more AT1 OEM devices will be ordered for it.
As AT1 CEO mentioned in FY20 results call, every OEM agreement signed up actually locks in the company that utilises their device long term. These RDTs need country regulator approval as a 'complete test' so if the developer wants to move to different RDT OEM, they will need to re-submit for regulatory approval everywhere....a costly and time consuming exercise..
Time will tell if FebriDx tests become a steady & high volume AT1 revenue river.....
